LON:VRP Verona Pharma plc (VRP.L) (VRP) Share Price, News & Analysis → Elon Musk’s Controversial New Project: “Apollo” (From InvestorPlace) (Ad) Free VRP Stock Alerts GBX 55 +3.00 (+5.77%) (As of 10/29/2020) Add Share Share Today's Range 50▼ 5650-Day Range 55▼ 5552-Week Range 28.60▼ 115Volume70,791 shsAverage Volume150,610 shsMarket Capitalization£228.00 millionAssets Under ManagementN/ADividend YieldN/ANet Expense Ratio0.00% Stock AnalysisStock Analysis Get Verona Pharma plc (VRP.L) alerts: Email Address About Verona Pharma plc (VRP.L) (LON:VRP)Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.Read More VRP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRP ETF News HeadlinesApril 18, 2024 | americanbankingnews.comVerona Pharma plc (VRP.L) (LON:VRP) Stock Price Passes Above 200-Day Moving Average of $55.00March 8, 2024 | markets.businessinsider.comStrong Buy Recommendation on Verona Pharma Backed by Positive Phase III Results and Robust Commercial StrategyApril 24, 2024 | InvestorPlace (Ad)Elon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...March 4, 2024 | markets.businessinsider.comBuy Rating Affirmed on Verona Pharma Ahead of Ensifentrine’s Expected FDA Approval and Strong Financial StandingFebruary 1, 2024 | markets.businessinsider.comMichael Austwick Joins Verona Pharma as Non-Executive DirectorJanuary 3, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Verona Pharma (VRNA)January 2, 2024 | msn.comVerona Pharma enters upto $400M debt facilityJanuary 1, 2024 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Verona Pharma (VRNA)April 24, 2024 | InvestorPlace (Ad)Elon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...November 3, 2023 | markets.businessinsider.comBuy Rating for Verona Pharma: Strong Potential of Ensifentrine, Attractive Entry Point and Solid FinancialsSee More Headlines Receive VRP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma plc (VRP.L) and its competitors with MarketBeat's FREE daily newsletter. Email Address 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Ad InvestorPlaceElon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...Click here to see the details because there's a lot of money at stake. Verona Pharma plc (VRP.L) (VRP)Full Holdings Details Key ExecutivesDr. Jan-Anders Karlsson (Age 64)CEO & Exec. Director Mr. Piers John Morgan (Age 53)Chief Financial Officer Ms. Claire Louise Poll L.C.S.W. (Age 52)B.A., B Juris, LLB, ASIA, Gen. Counsel Ms. Victoria StewartDirector of CommunicationsDr. Peter Spargo (Age 57)Sr. VP of Chemistry Manufacturing & Controls VRP ETF - Frequently Asked Questions How have VRP shares performed in 2024? Verona Pharma plc (VRP.L)'s stock was trading at GBX 55 at the beginning of 2024. Since then, VRP shares have increased by 0.0% and is now trading at GBX 55. View the best growth stocks for 2024 here. How were Verona Pharma plc (VRP.L)'s earnings last quarter? Verona Pharma plc (VRP.L) (LON:VRP) posted its quarterly earnings data on Thursday, February, 27th. The company reported ($30.30) EPS for the quarter, topping analysts' consensus estimates of ($30.80) by $0.50. What other stocks do shareholders of Verona Pharma plc (VRP.L) own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma plc (VRP.L) investors own include Verona Pharma (VRNA), Fate Therapeutics (FATE), Pluristem Therapeutics (PSTI), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), Grifols (GRFS) and Innoviva (INVA). How do I buy shares of Verona Pharma plc (VRP.L)? Shares of VRP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:VRP) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc (VRP.L) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
